Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects
: RNAi is a powerful tool for gene silencing that can be used to reduce undesirable overexpression of oncogenes as a novel form of cancer treatment. However, when using RNAi as a therapeutic tool there is potential for associated gene effects. This study aimed to utilize gold nanoparticles to delive...
Saved in:
Published in | Nanomedicine (London, England) Vol. 10; no. 16; pp. 2513 - 2525 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Future Medicine Ltd
01.08.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | : RNAi is a powerful tool for gene silencing that can be used to reduce undesirable overexpression of oncogenes as a novel form of cancer treatment. However, when using RNAi as a therapeutic tool there is potential for associated gene effects. This study aimed to utilize gold nanoparticles to deliver siRNA into HeLa cells.
: Knockdown of the c-myc oncogene by RNAi, at the RNA, protein and cell proliferation level was achieved, while also identifying associated gene responses.
: The gold nanoparticles used in this study present an excellent delivery platform for siRNA, but do note associated gene changes.
: The study highlights the need to more widely assess the cell physiological response to RNAi treatment, rather than focus on the immediate RNA levels. |
---|---|
AbstractList | : RNAi is a powerful tool for gene silencing that can be used to reduce undesirable overexpression of oncogenes as a novel form of cancer treatment. However, when using RNAi as a therapeutic tool there is potential for associated gene effects. This study aimed to utilize gold nanoparticles to deliver siRNA into HeLa cells.
: Knockdown of the c-myc oncogene by RNAi, at the RNA, protein and cell proliferation level was achieved, while also identifying associated gene responses.
: The gold nanoparticles used in this study present an excellent delivery platform for siRNA, but do note associated gene changes.
: The study highlights the need to more widely assess the cell physiological response to RNAi treatment, rather than focus on the immediate RNA levels. |
Author | Hernandez, Yulán de la Fuente, Jesus Maria Child, Hannah Winifred Berry, Catherine Cecilia Conde, João Mullin, Margaret Baptista, Pedro |
AuthorAffiliation | 6Instituto de Ciencia de Materiales de Aragón (ICMA), CSIC-Universidad de Zaragoza, c/Pedro Cerbuna 12, 50009 Zaragoza, Spain 1Centre for Cell Engineering, Joseph Black Building, Glasgow University, G12 8QQ, UK 5UCIBIO, CIGMH, Departamento de Ciencias da Vida, Faculdade de Ciencias e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, Portugal 4Integrated Microscopy Facility, Joseph Black Building, Glasgow University, G12 8QQ, UK 3Massachusetts Institute of Technology, Institute for Medical Engineering & Science, Harvard-MIT Division for Health Sciences & Technology, Cambridge, MA 02139-4307, USA 2Instituto de Nanociencia de Aragón, University of Zaragoza, C/Mariano Esquillor s/n Zaragoza, Spain |
AuthorAffiliation_xml | – name: 4Integrated Microscopy Facility, Joseph Black Building, Glasgow University, G12 8QQ, UK – name: 5UCIBIO, CIGMH, Departamento de Ciencias da Vida, Faculdade de Ciencias e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, Portugal – name: 6Instituto de Ciencia de Materiales de Aragón (ICMA), CSIC-Universidad de Zaragoza, c/Pedro Cerbuna 12, 50009 Zaragoza, Spain – name: 2Instituto de Nanociencia de Aragón, University of Zaragoza, C/Mariano Esquillor s/n Zaragoza, Spain – name: 1Centre for Cell Engineering, Joseph Black Building, Glasgow University, G12 8QQ, UK – name: 3Massachusetts Institute of Technology, Institute for Medical Engineering & Science, Harvard-MIT Division for Health Sciences & Technology, Cambridge, MA 02139-4307, USA |
Author_xml | – sequence: 1 givenname: Hannah Winifred surname: Child fullname: Child, Hannah Winifred – sequence: 2 givenname: Yulán surname: Hernandez fullname: Hernandez, Yulán – sequence: 3 givenname: João surname: Conde fullname: Conde, João – sequence: 4 givenname: Margaret surname: Mullin fullname: Mullin, Margaret – sequence: 5 givenname: Pedro surname: Baptista fullname: Baptista, Pedro – sequence: 6 givenname: Jesus Maria surname: de la Fuente fullname: de la Fuente, Jesus Maria – sequence: 7 givenname: Catherine Cecilia surname: Berry fullname: Berry, Catherine Cecilia |
BookMark | eNqdj81uwjAQhK0KpPLTQ99gH6BJ7aSG5FhVLZw4VNwty960BrOLYlNevw30CTjNjDSfRjMVI2JCIR6VLKtKLZ-JDqXSZavvxEQtX5pi0S7q0cXXhW6a9l5MU9pJqZtKyYnYrTh6IEt8tH0OLmKRwufmFQ7og83ogcnxFxLCntjtPZ8JbIahYsnDseeMgSDiD8YnOIf8DTYldlf4AmLXoctpLsadjQkf_nUm9Mf79m1ddKd86jG5gOTQXNMw7wKhUdIMx8zfMaO0aXV9K_cLXeFdtg |
ContentType | Journal Article |
Copyright | Future Medicine Ltd |
Copyright_xml | – notice: Future Medicine Ltd |
DOI | 10.2217/nnm.15.95 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1748-6963 |
EndPage | 2525 |
ExternalDocumentID | 10_2217_nnm_15_95 |
GroupedDBID | - 0R 123 29M 34G 39C 3V. 53G 70G 7X7 88E 8AO 8FI 8FJ ABUWG ACGFS ADBBV AENEX AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS BBAFP BENPR BPHCQ BVXVI CS3 DU5 EBS EHMNL F5P FYUFA H13 HZ IAO IEA IHR INH INR ITC M1P MV1 NTCAX O9- P2P PQEST PQQKQ PQUKI PRINS PROAC PSQYO RFM |
ID | FETCH-futurescience_futuremedicine_10_2217_nnm_15_953 |
ISSN | 1743-5889 |
IngestDate | Tue Jan 05 21:38:03 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-futurescience_futuremedicine_10_2217_nnm_15_953 |
ParticipantIDs | futurescience_futuremedicine_10_2217_nnm_15_95 |
ProviderPackageCode | NTCAX RFM 70G |
PublicationCentury | 2000 |
PublicationDate | 2015-August-01 |
PublicationDateYYYYMMDD | 2015-08-01 |
PublicationDate_xml | – month: 08 year: 2015 text: 2015-August-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Nanomedicine (London, England) |
PublicationYear | 2015 |
Publisher | Future Medicine Ltd |
Publisher_xml | – name: Future Medicine Ltd |
SSID | ssj0058210 |
Score | 4.259301 |
Snippet | : RNAi is a powerful tool for gene silencing that can be used to reduce undesirable overexpression of oncogenes as a novel form of cancer treatment. However,... |
SourceID | futurescience |
SourceType | Publisher |
StartPage | 2513 |
SubjectTerms | apoptosis c-myc cell cycle cell delivery cell proliferation gene knockdown gold nanoparticles knockdown nanoparticles off-target effects proliferation RNAi siRNA |
Title | Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects |
URI | http://dx.doi.org/10.2217/nnm.15.95 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDI7GdgEhxFO8lQO30bJ2Tdcep2ljQmwHBNI4Ve3aiMdIJdgu_DB-H3YeXQc7MC5Vm8ZpVH9ybCe2CblocZ46YdKyvLDBLC-NPSsYB2OrkfppywXExBz9kIOh33_wbkZsVKl8lU4tzaaJPf5cGlfyH65CG_AVo2RX4GwxKDTAPfAXrsBhuP6Jx9f5JK2LWIDhq15aH893w7YKB0FVMhfjHKiz-qsAuZeCxY3Bi9hF5QfIsdZlfYIHh_Bfq0A3zTAgl6T6xEdZiwWRnJtN-aU1QUr-BZk7WS5wsRDxE4gh8cxNfVDphC05sh9nE7lz7xSQ7cDQ2s0v3zTzOUQmuti8KdZb9mA4rDg_pzDXk8lT1MYUTnt-nAkFMqZQZYEqM2Rnpi2w_FALRiPFG2W0LshkpqJd9fruMhVp_XPtcF2ZcEqIN9thtqr8-SMVNxhM2CuCPpHDopCtkZrbChkY_bVufzC8NToARh_rUFw1e5XTComvig9skE2VN2ZB15F6zf022dIGCW0rAO2QSiZ2yUYpTeUeeUGc0d84owZn1OCMFjij8ZRiF2At1TijEmeXFFFG5yijklCjbJ-wXve-07cW5hypJwO56Ncfah6QqshFdkgo98PMC0IncQLuea6XgObOQ0wXFTg89vkRsVcb-3hVghOyPsffKalO32fZGeiU0-RcM_Ab0huCrA |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gold+nanoparticle-siRNA+mediated+oncogene+knockdown+at+RNA+and+protein+level%2C+with+associated+gene+effects&rft.jtitle=Nanomedicine+%28London%2C+England%29&rft.au=Child%2C+Hannah+Winifred&rft.au=Hernandez%2C+Yul%C3%A1n&rft.au=Conde%2C+Jo%C3%A3o&rft.au=Mullin%2C+Margaret&rft.date=2015-08-01&rft.pub=Future+Medicine+Ltd&rft.issn=1743-5889&rft.eissn=1748-6963&rft.volume=10&rft.issue=16&rft.spage=2513&rft.epage=2525&rft_id=info:doi/10.2217%2Fnnm.15.95&rft.externalDocID=10_2217_nnm_15_95 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-5889&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-5889&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-5889&client=summon |